Immunic to host virtual relapsing MS R&D Day on September 9

Health Pharma & Biotech Written by: Emily Jarvie 08:40 Wed 02 Sep 2026 --> Proactive has a commercial relationship with Immunic Inc. This article was produced independently under Proactive's Editorial Standards Policy . Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The Canberra Times, and... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Immunic Inc ( NASDAQ:IMUX ) View Price & Profile Immunic to host virtual relapsing MS R&D Day on September 9 Published: 08:40 02 Sep 2026 EDT Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will feature Immunic management, including CEO Erik Lundgren, chief medical officer Michael Panzara, chief scientific officer Hella Kohlhof and president and chief operating officer Jason Tardio. Multiple sclerosis specialists Amit Bar-Or of the Perelman School of Medicine at the University of Pennsylvania and Stephen Krieger of the Icahn School of Medicine at Mount Sinai Hospital will also participate. The company plans to discuss vidofludimus calcium, also known as IMU-838, its investigational oral small-molecule therapy for relapsing MS. Immunic is evaluating the treatment in the ENSURE Phase 3 program, with topline data expected by the end of the year. According to Immunic, vidofludimus calcium combines activation of nuclear receptor-related 1 (Nurr1) with selective inhibition of dihydroorotate dehydrogenase (DHODH). The company is investigating the therapy's potential to address both inflammatory and neurodegenerative mechanisms associated with MS. Bar-Or and Krieger will provide perspectives on the MS patient journey, existing treatment approaches and areas of unmet medical need. The R&D Day will take place from 11am to 12:30pm Eastern Time via Zoom on September 9. Registration is available through Immunic's website. Continue reading